THDB(SH:600867)2014-04-16 16:00Financial Performance - Operating income for the first quarter was CNY 328,765,960.94, representing a growth of 22.60% compared to CNY 268,166,834.79 in the same period last year[9]. - Net profit attributable to shareholders of the listed company rose by 20.80% to CNY 80,341,053.72 from CNY 66,509,904.45 year-on-year[9]. - Net profit for Q1 2014 reached CNY 79,622,002.35, representing a 22.3% increase from CNY 65,136,666.76 in Q1 2013[31]. - The main reason for the increase in operating revenue is the growth in sales of the recombinant human insulin products compared to the same period last year[6]. - The net profit attributable to the parent company's owners increased due to the growth in operating revenue from recombinant human insulin products, resulting in a year-on-year profit increase[6]. Cash Flow - Net cash flow from operating activities increased significantly by 469.17% to CNY 101,242,967.93 compared to CNY 17,787,887.84 in the previous year[9]. - Cash generated from operating activities was CNY 364,979,757.07, compared to CNY 284,486,192.36 in the previous year, reflecting a growth of 28.3%[36]. - Operating cash flow for Q1 2014 was ¥98,005,140.22, a significant increase from ¥15,354,304.78 in the same period last year, representing a growth of approximately 539%[42]. - Total cash inflow from operating activities was ¥356,161,534.62, compared to ¥263,603,904.45 in Q1 2013, indicating a year-over-year increase of about 35%[42]. - The net cash flow for the period was a decrease of ¥27,245,831.81, compared to an increase of ¥4,182,616.27 in the previous year[43]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,661,843,628.18, a decrease of 1.21% compared to the previous year-end[9]. - Total liabilities decreased to CNY 500,086,046.81 from CNY 607,653,799.00 year-over-year[27]. - Current liabilities totaled approximately ¥263.44 million, down from ¥375.04 million at the beginning of the year, indicating improved liquidity[23]. - The company reported a decrease in inventory from approximately ¥343.78 million to ¥310.74 million, indicating improved inventory management[21]. Shareholder Information - The number of shareholders at the end of the reporting period was 57,831[12]. - The largest shareholder, Dongbao Industrial Group Co., Ltd., held 36.06% of the shares, totaling 335,890,339 shares[12]. Equity and Return - Net assets attributable to shareholders of the listed company increased by 4.01% to CNY 2,070,986,901.99 from CNY 1,991,181,348.27[9]. - The weighted average return on net assets improved by 0.63 percentage points to 3.96% from 3.33%[9]. - Shareholders' equity increased to CNY 2,188,309,349.28 from CNY 2,104,699,838.23, marking a growth of 4.0%[27]. Investment Activities - The net cash flow from investing activities was negative at approximately -¥9.92 million, an improvement from -¥57.80 million in the previous year, indicating reduced investment losses[18]. - Investment income for Q1 2014 was CNY 2,101,646.77, significantly higher than CNY 633,023.27 in Q1 2013[30]. - Investment activities resulted in a net cash outflow of ¥7,986,369.41, a decrease from ¥56,741,661.15 in Q1 2013, showing a reduction of approximately 86%[43]. Financing Activities - Short-term borrowings decreased by 43.48% to CNY 143,000,000.00 from CNY 253,000,000.00 due to repayment of working capital loans[16]. - Cash inflow from financing activities was ¥30,000,000.00, down from ¥49,600,000.00 in the same quarter last year, representing a decline of about 40%[43]. - Total cash outflow from financing activities reached ¥147,264,602.62, significantly higher than ¥3,840,843.57 in Q1 2013, indicating a substantial increase[43]. Foreign Exchange Impact - The company experienced a negative impact of ¥189,183.79 from foreign exchange fluctuations on cash and cash equivalents[43].